secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001558370-23-008825
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azenta Q2 FY23 revenue $148M, GAAP EPS loss $0.03, guided Q3 below consensus
----------------------------------------------------------------------------

- Revenue $148M (+2% YoY; -17% sequentially); non-GAAP diluted EPS ($0.06) vs $0.12 a year ago.
- Life Sciences Products revenue $59M (+10% YoY) but B Medical $15M, below expectations due to order delays.
- Adjusted EBITDA ($2.4M) vs $19M prior year; expects $15M annual cost savings from realignment.
- Realigns into three groups (Multi-Omics, Sample Management, B Medical) effective Oct 1, 2023.
- Q3 FY23 guidance: revenue $150-168M; non-GAAP EPS ($0.07)-$0.03; GAAP EPS ($0.29)-($0.19).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000155837023008825/0001558370-23-008825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000155837023008825/azta-20230509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer